Animal Models for Inborn Lysosomal Storage Diseases
نویسندگان
چکیده
منابع مشابه
Lysosomal storage diseases
Lysosomes are cytoplasmic organelles that contain a variety of different hydrolases. A genetic deficiency in the enzymatic activity of one of these hydrolases will lead to the accumulation of the material meant for lysosomal degradation. Examples include glycogen in the case of Pompe disease, glycosaminoglycans in the case of the mucopolysaccharidoses, glycoproteins in the cases of the oligosac...
متن کاملClarifying lysosomal storage diseases.
Lysosomal storage diseases (LSDs) are a class of metabolic disorders caused by mutations in proteins critical for lysosomal function. Such proteins include lysosomal enzymes, lysosomal integral membrane proteins, and proteins involved in the post-translational modification and trafficking of lysosomal proteins. There are many recognized forms of LSDs and, although individually rare, their combi...
متن کاملLysosomal Storage Diseases-Regulating Neurodegeneration.
Autophagy is a complex pathway regulated by numerous signaling events that recycles macromolecules and can be perturbed in lysosomal storage diseases (LSDs). The concept of LSDs, which are characterized by aberrant, excessive storage of cellular material in lysosomes, developed following the discovery of an enzyme deficiency as the cause of Pompe disease in 1963. Great strides have since been m...
متن کاملLysosomes and Lysosomal Storage Diseases
157 in the delivery room, and the normal newborn with a number of very pertinent sections about the situations in which the neonate finds himself in most serious trouble. The chapter on assessment of gestational age, for example, has both pictures and charts which will allow the physician to compare the physical examination in the patient with established standards. Pictures are of excellent qu...
متن کاملEnzyme replacement therapy for lysosomal storage diseases.
Enzyme replacement therapy (ERT) has been approved for 6 lysosomal storage diseases (LSDs) worldwide including Japan. These diseases include Gaucher disease (GD), Fabry disease, mucopolysaccharidosis (MPS) types I, II, and VI, and Pompe disease (PD). The efficacy and safety of ERT for LSDs has been confirmed by extensive clinical trials. However, there are still obstacles to successful ERT, suc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: EXPERIMENTAL ANIMALS
سال: 1977
ISSN: 0007-5124,1884-4170
DOI: 10.1538/expanim1957.26.1_65